When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
An endogenous hallucinogenic compound binds to a ligand-gated chaperone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826 · cited 13×
“Sig-1R ligands, including DMT, at concentrations close to their Ki values, cause the dissociation of Sig-1Rs from another ER chaperone, binding immunoglobulin protein (BiP) (34), allowing Sig-1Rs to chaperone inositol 1,4,5-trisphosphate receptors (IP3Rs) at the MAM (34).”
BackgroundSelf-citationMAM: more than just a housekeeper
Hayashi, T., Rizzuto, R., Hajnoczky, G., & Su, T.-P. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.12.002 · Cited by 787
Self-citationThe Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303
Enzymatic formation of psychotomimetic metabolites from normally occurring compounds
Axelrod, J. (1961) · Science · doi:10.1126/science.134.3475.343 · Cited by 184 · cited 1×
“For example, the enzyme that synthesizes DMT from its precursor tryptamine (44) and Sig-1Rs (34) are particularly abundant in lung tissue.”
BackgroundDifferential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors
Deliganis, A. V., Pierce, P. A., & Peroutka, S. J. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90178-8 · Cited by 73
Cited by
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
The pharmacology of sigma-1 receptors.
Maurice, T., & Su, T.-P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.001 · Cited by 654
“…in a recent article, which speculates that overexpression of sigma-1 receptor agonists or administration of sigma-1 agonists might cause the translocation of sigma-1 receptors from the ER to the sub-plasma membrane area where sigma-1 receptors might interact with ion channels (Su et al., 2009).”
BackgroundInfluentialSelf-citationThe sigma-1 receptor chaperone as an inter-organelle signaling modulator
Su, T.-P., Hayashi, T., Maurice, T., Buch, S., & Ruoho, A. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.007 · Cited by 466
Self-citationPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242
“It is assumed that the Sig-1R might be involved in the DMTinduced psychedelic effects (Su et al., 2009); however, this is somewhat counterintuitive since many drugs—including nonhallucinogens—bind promiscuously to the Sig-1R with higher affinity than DMT.”
BackgroundClinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“Many suggestions have been put forth regarding DMTs physiological role in the body, though there is no widely accepted consensus (Burchett & Hicks, 2006; Callaway, 1988; Frecska et al., 2013; Jacob & Presti, 2005; Su et al., 2009).”
BackgroundSzabo, A., Kovacs, A., Frecska, E., & Rajnavolgyi, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106533 · Cited by 191
Barker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Szabo, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00358 · Cited by 150
Barker, S. A., McIlhenny, E. H., & Strassman, R. (2012) · Drug Testing and Analysis · doi:10.1002/dta.422 · Cited by 142
Morales-Garcia, J. A., Calleja-Conde, J., Lopez-Moreno, J. A., Alonso-Gil, S., Sanz-SanCristobal, M., Riba, J., & Perez-Castillo, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01011-0 · Cited by 138
Szabo, A., Kovacs, A., Riba, J., Djurovic, S., Rajnavolgyi, E., & Frecska, E. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00423 · Cited by 121
Frecska, E., Szabo, A., Winkelman, M. J., Luna, L. E., & McKenna, D. J. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1024-y · Cited by 109
Blough, B. E., Landavazo, A., Decker, A. M., Partilla, J. S., Baumann, M. H., & Rothman, R. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3557-7 · Cited by 101
“2001), and the sigma-1 receptor (Fontanilla et al. 2009; Su et al. 2009) have also been suggested to modulate the effects of hallucinogenic compounds.”
BackgroundBarker, S. A., Borjigin, J., Lomnicka, I., & Strassman, R. (2013) · Biomedical Chromatography · doi:10.1002/bmc.2981 · Cited by 72
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
In Vivo Long-Term Kinetics of Radiolabeled N,N-Dimethyltryptamine and Tryptamine
Vitale, A. A., Pomilio, A. B., Cañellas, C. O., Vitale, M. G., Putz, E. M., & Ciprian-Ollivier, J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.083246 · Cited by 48
“However, it is unclear whether TAARs are associated with psychodysleptic effect, and controversies have arisen concerning TAARs involved in schizophrenic symptomatology (13).”
BackgroundKelley, D. P., Venable, K., Destouni, A., Billac, G., Ebenezer, P., Stadler, K., Nichols, C., Barker, S., & Francis, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00660 · Cited by 42
The therapeutic potentials of Ayahuasca in the treatment of depression
Palhano-Fontes, F., Alchieri, J. C., Oliveira, J. P. M., Soares, B. L., Hallak, J. E. C., Galvao-Coelho, N., & de Araujo, D. B. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_2 · Cited by 36
“Therefore, high intracellular and vesicular concentrations of DMT may be achieved inside of neurons, and can interact with intracellular sigma1 receptors located in the mitochondria-associated endoplasmic reticulum membrane (Su et al. 2009).”
Background
Metadata
- Authors
- Su, T.-P., Hayashi, T., & Vaupel, D. B.
- Venue
- Science Signaling
- Published
- 2009-03-10
- Volume
- 2
- Issue
- 61
- Pages
- pe12-pe12
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2074731904
- Cited by
- 110
- References
- 10
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.